Chinese Biopharmaceuticals: The Board of Directors resolved to approve a share buyback plan of no more than 2 billion Hong Kong dollars.

Chinese biopharmaceutical company announced on the Hong Kong Stock Exchange that the board of directors decided on June 12 to approve a share purchase plan. According to this plan, the company will, based on market conditions, repurchase shares in the open market for a total consideration not exceeding HKD 2 billion over the next 12 months, in accordance with the share repurchase authorization obtained at the annual general meeting of shareholders and subject to the terms and conditions thereof. The company will repurchase shares and instruct the trustee responsible for managing the share incentive plan to purchase shares in accordance with the restricted share incentive plan adopted by the company on January 5, 2018. As of early 2026, the company has also accumulated purchases of 60,350,000 shares, totaling approximately HKD 338 million.